La cadena de opciones muestra datos clave de las opciones de acciones de Sportradar Gr a varios precios de ejercicio y fechas de vencimiento. Los operadores utilizan esta información para analizar posibles operaciones y evaluar el sentimiento del mercado para Sportradar Gr..

Sportradar Gr (NASDAQ:SRAD) Bolsa, Cadena de Opciones

Sportradar Gr

Sportradar Group AG is a technology platform enabling next-generation engagement in sports, and a provider of B2B solutions to the sports betting industry. It generates revenue through two primary sources: subscription-based revenue and revenue sharing. Geographically, it operates in North America, Africa, AsiaPac & Middle East, Europe, and LATAM & Caribbean.

Sportradar Group AG - Class A Ordinary Shares

Sportradar Group AG

Juvena Therapeutics, Inc. on Wednesday entered a global licensing and <a href="https://www.benzinga.com/topic/pharmaceuticals">multi-target research collaboration</a> with Eli Lilly And Co (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>). 
The two companies aim to develop and commercialize drug candidates that improve <a href="https://www.benzinga.com/topic/weight-loss" target="_blank" rel="noreferrer noopener">muscle health and body composition</a>.
Juvena <a href="https://www.globenewswire.com/news-release/2025/06/11/3097451/0/en/Juvena-Therapeutics-and-Lilly-Enter-Research-Collaboration-Focused-on-Muscle-Health.html" target="_blank" rel="noreferrer noopener">will</a> leverage JuvNET, an AI-enabled screening platform for mapping the therapeutic potential of stem cell-secreted proteins, developed by Juvena.
The collaboration will identify muscle-targeting drug candidates from Juvena's proprietary library of human stem-cell secreted proteins for improved body composition and muscle health.
Also Read: <a target="_blank" href="https://www.benzinga.com/news/health-care/25/06/45834370/eli-lillys-obesity-drug-success-spurs-japanese-biotechs-anti-muscle-wasting-combo-therapy" rel="noreferrer noopener">Eli Lilly&#8217;s Obesity Drug Success Spurs Japanese Biotech&#8217;s Anti-Muscle-Wasting Combo Therapy</a>
Juvena Therapeutics is showcasing how its AI-driven discovery platform can accelerate the development of regenerative therapies for chronic diseases like obesity and frailty, Hanadie Yousef, co-founder and CEO of Juvena Therapeutics, explained.
The company focuses on pro-metabolic and muscle-regenerative treatments, driven by growing evidence that improving muscle health can enhance metabolism, mobility, and long-term disease resilience. By leveraging its proprietary library of stem-cell-derived proteins, Juvena aims to uncover novel therapeutic targets and bring more effective treatments to patients with greater precision and speed
Under the agreement, Juvena will receive an upfront payment, an equity investment, and potential development and commercialization milestone payments.
Juvena will grant Lilly an exclusive license to identified lead candidates and Lilly will be responsible for further research, development, and commercialization.
Juvena's pipeline of biologic drug candidates spans chronic muscle and obesity-related diseases.
In May, Juvena&nbsp;<a target="_blank" href="https://www.globenewswire.com/Tracker?data=iX2tz27fYL84UbK6_wCVTJ7yIVpwIMZKbweUugu-pA4cQi0X5LiEO8nbCAJwJFRgZcHp7pe86HK3INYNJ00gJ2yjcVKfrdygnUdtFaa9ADRvpqV4y3BYFN8Rayzoe9fdEiBHFunBqEJQ6g5AcZFxlhlbV2_AoNJIUWSLKe6mm3uATcMjcz0koumA04ZcuNGi8cm9r0mbr4S6le6HjgQkjOq3FqasqdK9kZWfLuv-FCWYiLXZ1y8uFIrIqdiGMxIK" rel="noreferrer noopener">announced</a>&nbsp;the first clinical trial for its lead program, JUV-161, engineered from a naturally secreted protein that enhances muscle regeneration and health.
They are also developing JUV-112, a lipolysis inducing, non-appetite suppressing, muscle sparing, obesity and metabolic disease preclinical candidate with an energy expenditure mechanism of action that is based on the discovery of a secreted protein that is orthogonal to incretins.
The company has also generated dozens of hits with tissue restorative benefits spanning pulmonary and hepatic fibrosis and osteoarthritis.
Last week, Swedish biopharmaceutical company&nbsp;Camurus AB&nbsp;entered a collaboration and <a target="_blank" href="https://www.benzinga.com/news/health-care/25/06/45769020/mounjaro-maker-eli-lilly-taps-swedish-firm-camurus-to-target-long-acting-obesity-market-in-870-million-deal" rel="noreferrer noopener">license agreement&nbsp;with&nbsp;Eli Lilly</a>.
Camurus granted Eli Lilly exclusive rights to research, develop, manufacture, and commercialize long-acting incretin products for cardiometabolic health based on Camurus' FluidCrystal technology.
The agreement&nbsp;comprises&nbsp;up to four Lilly proprietary drug compounds, selected from dual GIP and GLP-1 receptor agonists, triple GIP, glucagon, and GLP-1 receptor agonists, and an option to include amylin receptor agonists.
Price Action: Eli Lilly stock is up 0.75% at $813.28 at the last check on Wednesday.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/news/health-care/25/06/45844858/metsera-stock-rises-as-company-advances-obesity-pipeline-with-encouraging-weight-loss-data" target="_blank" rel="noreferrer noopener">Metsera Stock Rises As Company Advances Obesity Pipeline With Encouraging Weight Loss Data</a></li>
</ul>
Image: Shutterstock

Biotech

Large Cap

News

Health Care

Contracts

General

Eli Lilly Inks Pact With Juvena Therapeutics To Develop Muscle-Boosting Drugs

WIIM

QBTS

QMCO

QUBT

RGTI

Shares of quantum-linked stocks are trading higher after Nvidia CEO Jensen Huang said that quantum computers will soon be able to solve complex, real-world problems that are out of reach for classical computers.

Reuters Reports U.S. Commerce Secretary Lutnick Says Deal After Deal Will Start Coming Next Week

Shares of domestic steel producers, including Cleveland-Cliffs Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CLF#NYSE">CLF</a>), faced significant downward pressure Wednesday morning following reports of a potential trade deal between the United States and Mexico. The proposal would see the removal of the Trump Administration&#8217;s 50% tariffs on Mexican <a href="https://www.benzinga.com/markets/tech/25/06/45786145/trumps-50-steel-tariff-could-drive-up-the-costs-for-automakers-almost-2000-of-cost-for-each-car">steel imports</a> up to a certain quota.
What To Know: The tentative agreement, <a href="https://www.bloomberg.com/news/articles/2025-06-10/us-and-mexico-near-deal-to-cut-steel-duties-and-cap-imports">reportedly</a> being spearheaded by Commerce Secretary Howard Lutnick, aims to establish a cap on tariff-free steel imports based on historical trade volumes. This development marks a potential reversal of the steep tariffs announced at the end of May, which were intended to bolster the American steel industry. 
While the deal still requires final approval from President Donald Trump, the prospect of increased import competition has sent ripples through the steel sector.
The market reaction was swift, with investors selling off shares in major U.S. steel companies late Tuesday. The move reflects concerns that an influx of tariff-free Mexican steel could lead to oversupply and depress domestic prices, impacting profitability for companies like Cleveland-Cliffs.
Price Action: According to data from <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>, shares of Cleveland-Cliffs were trading down 7.98% at $7.38 Wednesday morning. The stock also has a significant short interest, with 32.57% of the float being sold short.
Read Also: <a href="https://www.benzinga.com/markets/economic-data/25/06/45881899/inflation-resumes-climb-in-may-but-tariffs-have-yet-to-hit-consumers">Inflation Resumes Climb In May, But Tariffs Have Yet To Hit Consumers</a>
<h2 class="wp-block-heading">How To Buy CLF Stock</h2>
Besides going to a brokerage platform to purchase a share &#8211; or fractional share &#8211; of stock, you can also gain access to shares either by buying an exchange traded fund (ETF) that holds the stock itself, or by allocating yourself to a strategy in your 401(k) that would seek to acquire shares in a mutual fund or other instrument. 
For example, in Cleveland-Cliffs&#8217; case, it is in the Materials sector. An ETF will likely hold shares in many liquid and large companies that help track that sector, allowing an investor to gain exposure to the trends within that segment.
According to data from Benzinga Pro, CLF has a 52-week high of $16.47 and a 52-week low of $5.63.

Cleveland-Cliffs (CLF) Stock Tumbles On US-Mexico Steel Tariff Deal Report

A recent <a href="https://www.reddit.com/r/skilledtrades/comments/1l5tyj5/why_do_people_think_trades_are_easy/">post</a> on Reddit&#8217;s r/skilledtrades titled, &#8220;Why do people think trades are easy?&#8221; stirred up a tremendous response after one user pushed back on the common idea that trades are an easy escape from white-collar burnout or from being <a href="https://www.benzinga.com/markets/equities/25/02/43761822/jamie-dimon-says-ai-will-change-your-jobs-but-it-may-eliminate-some-careers-as-well-reskill-and-redeploy-people">replaced by artificial intelligence</a>.
<h2 class="wp-block-heading">&#8216;This Can&#8217;t Be My Life&#8217;</h2>
The post came from a chemical engineer by training who moved to Canada but couldn't find work in his field because his degree wasn&#8217;t recognized. So, he pivoted to the trades and became a mechanical insulator. &#8220;I'm working as a mechanical insulator. We insulate pipes and ducts, mostly around Alberta. The money's decent. I'm getting $24 an hour as a first year,&#8221; he wrote. They did not specify whether it was Canadian or U.S. dollars.
Don't Miss:
<ul class="wp-block-list">
<li>Maker of the $60,000 foldable home has 3 factory buildings, 600+ houses built, and big plans to solve housing — <a href="https://www.benzinga.com/money/boxabl-scaling-fast-from-spacex-orders-to-600-homes-built-this-60k-foldable-home-may-be-the-future-of-housing">this is your last chance to become an investor for $0.80 per share.</a></li>
<li>Deloitte's fastest-growing software company partners with Amazon, Walmart &amp; Target – <a href="https://www.benzinga.com/money/how-peter-thiel-turned-his-roth-ira-into-5-billion-and-why-accredited-investors-are-now-eyeing-this-smartphone-disruptor">Many are rushing to grab 4,000 of its pre-IPO shares for just $0.30/share!</a></li>
</ul>
Even though he&#8217;s young and in good shape, the reality of the job hit him hard. &#8220;Waking up at 5 a.m., out in the cold when it's -25, lifting, sweating, doing the same thing every day. Even though my trade isn't the most physically intense, it's still tough on your body,&#8221; he said.
What frustrates him is how people treat trades like an easy exit from the office grind. &#8220;People really need to stop acting like trades are some kind of escape from a boring office job. You want real hours? When you work trades, you work for real. Ten hours means ten hours. No breaks to scroll your phone or chill at your desk. It's all go.&#8221;
<h2 class="wp-block-heading">Not Just About The Money</h2>
While many assume trades come with better pay and more job satisfaction, the original poster pointed out the ceiling that exists for most in his field. &#8220;Most tradespeople max out at journeyperson level. In rare cases, someone might move into something bigger, but for most, that's it.&#8221;
Trending: Invest where it hurts — and help millions heal:<a href="https://www.benzinga.com/money/a-cure-for-osteoarthritis-powered-by-everyday-investors-cytonics-is-looking-to-beat-big-pharma-and-disrupt-a-390-billion-market"> Invest in Cytonics and help disrupt a $390B Big Pharma stronghold</a>.
He added, &#8220;Even if you gave me $100 an hour, I wouldn't want to stay. I need to do something I actually enjoy, something I see myself growing in.&#8221;
Dozens of tradespeople chimed in, with a mix of support and straight talk. One electrician said, &#8220;It depends on the trade honestly&#8230; Some people can't handle the trades, no matter what trade you pick.&#8221;
Others shared similar frustrations about the glamorized perception of trades online. &#8220;Social media is filling people's heads with the idea that the trades are easy money,&#8221; wrote an overhead crane technician. &#8220;What they don't tell you is the long days and nights, the on calls, and the working out of town away from family.&#8221;
Many agreed with OP&#8217;s view that some trades are simply too grueling to be sustainable for a full career. &#8220;Fiberglass is killing me every single day,&#8221; he said. &#8220;It's in my clothes, on my skin, in my eyes. People don't talk about that part. Trades look good from the outside, but inside? It's tough on your body and your mind.&#8221;
Still, some pushed back on the idea that trades lack intellectual challenge. &#8220;It's surprising to some people how intelligent a lot of people in the trades are,&#8221; one commenter said. &#8220;Some could have gone on to be engineers or doctors but went into [heating, ventilation and air conditioning], electrical, or mechanics.&#8221;
See Also: <a href="https://www.benzinga.com/money/gbr-savings-by-age">If You're Age 35, 50, or 60: Here&#8217;s How Much You Should Have Saved Vs. Invested By Now</a>
<h2 class="wp-block-heading">Mike Rowe: Time To Invest In The Trades</h2>
Mike Rowe, known for the TV show &#8220;Dirty Jobs,&#8221; has long advocated for more respect and funding for skilled labor. Speaking to <a href="https://www.youtube.com/watch?v=9TzgDH_FMos">Fox Business</a> recently, he <a href="https://www.benzinga.com/news/topics/25/06/45754862/peter-schiff-agrees-with-trump-that-college-isnt-worth-it-for-most-his-fix-scrap-the-minimum-wage-and-let-kids-learn-trades-on-the-job">supported Trump's idea</a> to redirect funds from elite universities to trade schools. &#8220;If I had to choose between should <a href="https://www.benzinga.com/25/05/45578777/trump-administration-revokes-harvards-ability-to-enroll-international-students-kristi-noem-alleges-coordination-with-chinese-communist-party">Harvard get $3 billion</a> or trade schools in that world—trade schools,&#8221; he said.
But Rowe cautioned that not all trade programs are created equal and called for better evaluation. He also emphasized the growing demand for skilled labor, noting that just one call from the maritime sector requested 140,000 tradespeople over the next decade.
&#8220;If you have a skill that's in demand and you&#8217;re hungry, if you are willing to get up early, stay late and go to where the work is… you are going to crush it,&#8221; Rowe said.
Read Next:
<ul class="wp-block-list">
<li>Maximize saving for your retirement and cut down on taxes: <a href="https://www.benzinga.com/money/wideradvisor-retirement-planning">Schedule your free call with a financial advisor to start your financial journey – no cost, no obligation</a>. </li>
<li>Inspired by Uber and Airbnb &#8211; Deloitte's fastest-growing software company is transforming 7 billion smartphones into income-generating assets &#8211; <a href="https://www.benzinga.com/money/how-peter-thiel-turned-his-roth-ira-into-5-billion-and-why-accredited-investors-are-now-eyeing-this-smartphone-disruptor">with $1,000 you can invest at just $0.30/share!</a></li>
</ul>
Image: Shutterstock

A Skilled Trader Asks, 'Why Do People Think Trades Are Easy?' Swapping Office Life For Manual Work Isn't The Shortcut People Imagine

Bread Financial Holdings shares are trading higher after the company reported a year-over-year decrease in May net loss rate and May delinquency rate.

<a href="https://www.bloomberg.com/news/articles/2025-06-11/uber-alleges-insurance-fraud-scheme-in-florida-as-it-goes-on-legal-offensive?embedded-checkout=true">https://www.bloomberg.com/news/articles/2025-06-11/uber-alleges-insurance-fraud-scheme-in-florida-as-it-goes-on-legal-offensive?embedded-checkout=true</a>

UBER

'Uber Alleges Insurance Fraud Scheme in Florida as It Goes on Legal Offensive'- Bloomberg

Lululemon Athletica (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LULU#NASDAQ">LULU</a>) has outperformed the market over the past 15 years by 5.88% on an annualized basis producing an average annual return of 17.77%. Currently, Lululemon Athletica has a market capitalization of $32.24 billion. 
Buying $1000 In LULU: If an investor had bought $1000 of LULU stock 15 years ago, it would be worth $11,293.11 today based on a price of $257.37 for LULU at the time of writing.
<h3>Lululemon Athletica's Performance Over Last 15 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1749654912_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Trading Ideas

LULU

$1000 Invested In Lululemon Athletica 15 Years Ago Would Be Worth This Much Today

Novavax, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVAX#NASDAQ">NVAX</a>) announced results Wednesday of the initial cohort of its COVID-19-Influenza Combination (CIC) and standalone trivalent hemagglutinin nanoparticle seasonal <a href="https://www.benzinga.com/general/health-care" target="_blank" rel="noreferrer noopener">influenza (tNIV) Phase 3 trial</a>.
The study showed that the CIC and flu vaccine candidates induced immune responses similar to those of licensed comparators Nuvaxovid&nbsp;and Sanofi SA&#8217;s (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SNY#NASDAQ">SNY</a>) <a target="_blank" href="https://www.benzinga.com/pressreleases/25/06/n45879363/novavaxs-covid-19-influenza-combination-and-stand-alone-influenza-vaccine-candidates-showed-robust" rel="noreferrer noopener">Fluzone HD, respectively</a>.
Both standalone flu and CIC vaccine candidates induced robust immune responses to the vaccine strains (2.4-5.7-fold over baseline).
Also Read: <a target="_blank" href="https://www.benzinga.com/25/05/45624037/robert-f-kennedy-jr-says-cdc-drops-covid-vaccine-for-healthy-pregnant-women-kids" rel="noreferrer noopener">Robert F. Kennedy Jr. Says CDC Drops COVID Vaccine For &#8216;Healthy&#8217; Pregnant Women, Children</a>
&#8220;Both our combination and standalone flu vaccine candidates induced robust immune responses and were well tolerated,&#8221; said Ruxandra Draghia-Akli, executive vice president and head of Research and Development at Novavax.
&#8220;This&nbsp;data set adds to&nbsp;findings from our Phase 2 trial and will help inform discussions with potential partners.&#8221;
Both vaccine candidates were well tolerated and saw reactogenicity comparable to authorized comparators.
Nearly all (&gt;98%) solicited adverse events were mild or moderate in severity.&nbsp;
The cohort was designed to provide descriptive data on three flu strains&nbsp;(H1N1, H3N2, B) and SARS-CoV-2 (COVID-19) to inform a future registrational Phase 3 program.
The descriptive trial evaluated the safety and immunogenicity of the CIC and standalone flu vaccine candidates&nbsp;compared to Nuvaxovid and Fluzone HD in approximately 2,000 adults&nbsp;aged 65 and older.
This trial was not adequately powered to demonstrate statistical significance.
In May 2023, Novavax unveiled data for its COVID-influenza combination vaccine and&nbsp;<a target="_blank" href="https://www.benzinga.com/general/biotech/23/05/32287464/novavax-eases-uncertainty-announces-job-cuts-encouraging-data-from-covidflu-combo-shot" rel="noreferrer noopener">two other shots</a>.
Data from a Phase 2 trial in adults aged 50-80 showed that the combination shot produced an immune response comparable to its protein-based COVID vaccine and already approved influenza shots.
The study found that all three of Novavax&#8217;s vaccine candidates—the COVID/flu combination shot, a standalone flu shot, and a higher dose of its COVID shot—were safe and well-tolerated.
In May, Novavax received limited approval from the U.S. Food and Drug Administration (FDA) for its COVID-19 vaccine, Nuvaxovid. This marked a regulatory milestone and unlocking a $175 million milestone payment <a href="https://www.benzinga.com/25/05/45496095/novavax-scores-key-fda-win-shares-jump-19-as-sanofi-milestone-unlock" target="_blank" rel="noreferrer noopener">from partner Sanofi</a>.
Earlier in June, the FDA approved&nbsp;Moderna, Inc.'s&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRNA#NASDAQ">MRNA</a>) mNexspike&nbsp;(mRNA-1283), a new vaccine against COVID-19, for all adults 65 and older and individuals aged 12-64 years with at least one or more underlying risk factor as defined by the Centers for Disease&nbsp;<a target="_blank" href="https://www.benzinga.com/news/fda/25/06/45719840/modernas-new-covid-vaccine-secures-fda-clearance-for-seniors-at-risk-individuals" rel="noreferrer noopener">Control and Prevention (CDC)</a>.
Price Action: NVAX stock is up 0.56% at $7.24 at the last check on Wednesday.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/news/health-care/25/06/45854247/american-pharmacists-association-withholds-endorsement-of-cdcs-revised-covid-19-vaccine-guidance" target="_blank" rel="noreferrer noopener">American Pharmacists Association Withholds Endorsement Of CDC&#8217;s Revised COVID-19 Vaccine Guidance</a></li>
</ul>
Photo: Shutterstock

MRNA

NVAX

Novavax's Experimental COVID-19-Influenza Combo Shot Shows Immune Response Among Older Adults In Phase 3 Trial

Economics

Reuters Reports U.S. Commerce Secretary Lutnick Says China Is Going To Approve All Applications For Magnets For US Companies; Trump-Xi Has To Approve Final Wording; Chinese Side Always Wants To Remove Export Controls; They've Agreed We Are Going To Examine How China Can Do More Business With Us;  You Can Say China Tariff Levels Won't Change From Here; We Are Not Going To Give China Our Best Chips

BigBear.ai Holdings Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BBAI#NYSE">BBAI</a>) saw its stock price climb early Wednesday following the announcement of a strategic partnership with Easy Lease PJSC, a mobility solutions provider in the United Arab Emirates.
What To Know: The <a href="https://www.benzinga.com/pressreleases/25/06/b45881266/bigbear-ai-easy-lease-and-vigilix-announce-strategic-partnership-in-the-uae">collaboration</a> is aimed at accelerating the development and deployment of artificial intelligence solutions to drive digital transformation across the UAE and the wider region.
The partnership will leverage BigBear.ai&#8217;s expertise in mission-ready AI, Easy Lease&#8217;s operational scale and market reach, and Vigilix&#8217;s regional insights. The joint effort will focus on creating practical, scalable technologies for mobility, industrial and other high-growth sectors, supporting the UAE&#8217;s innovation agenda. 
Kevin McAleenan, CEO of BigBear.ai, called the <a href="https://www.benzinga.com/pressreleases/25/06/b45881266/bigbear-ai-easy-lease-and-vigilix-announce-strategic-partnership-in-the-uae">partnership</a> a &#8220;milestone&#8221; and a &#8220;major first step&#8221; in the company&#8217;s international expansion plans.
In early trading Wednesday, shares of BBAI were up around 3.45%, trading around $3.90. According to data from <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>, the stock has experienced significant volatility, with a 52-week range of $1.16 to $10.36.
Notably, there is substantial short interest in the stock, with 32.57% of the float currently sold short, indicating a significant number of investors are betting against the company&#8217;s share price.
Read Also: <a href="https://www.benzinga.com/news/25/06/45882971/wall-street-eyes-record-highs-as-trump-seals-china-deal-soft-inflation-eases-tariff-jitters">Wall Street Eyes Record Highs As Trump Seals China Deal, Soft Inflation Eases Tariff Jitters</a>
<h2 class="wp-block-heading">How To Buy BBAI Stock</h2>
Besides going to a brokerage platform to purchase a share &#8211; or fractional share &#8211; of stock, you can also gain access to shares either by buying an exchange traded fund (ETF) that holds the stock itself, or by allocating yourself to a strategy in your 401(k) that would seek to acquire shares in a mutual fund or other instrument. 
For example, in BigBear.ai&#8217;s case, it is in the Information Technology sector. An ETF will likely hold shares in many liquid and large companies that help track that sector, allowing an investor to gain exposure to the trends within that segment.
According to data from Benzinga Pro, BBAI has a 52-week high of $10.36 and a 52-week low of $1.16.
Image: Shutterstock

BBAI

BigBear.ai (BBAI) Announces Strategic UAE Partnership: What's Going On?

GameStop Corp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GME#NYSE">GME</a>) shares are trading lower Wednesday on the heels of the company&#8217;s first-quarter financial results. Here&#8217;s what you <a href="https://www.benzinga.com/markets/earnings/25/06/45872536/gamestop-q1-earnings-revenue-misses-despite-collectibles-growth-eps-beats-retailer-adds-4710-bitcoin">need to know</a>.
What To Know: GameStop reported mixed results for the first quarter with revenue coming in at $732.4 million, below analyst&nbsp;<a href="https://www.benzinga.com/quote/GME/earnings" target="_blank" rel="noreferrer noopener">estimates</a>&nbsp;of $754.24 million, and adjusted earnings per share totaling 17 cents, above estimates of four cents.
GameStop said total revenue fell about 17% year-over-year as hardware and accessories revenue of $345.3 million was down from $505.3 million in the prior year&#8217;s quarter and software revenue declined from $239.7 million to $175.6 million. Meanwhile, Collectibles revenue increased from $136.8 million to $211.5 million year-over-year.
GameStop ended the period with approximately $6.4 billion in cash, cash equivalents and marketable securities. Subsequent to quarter&#8217;s end, the company used cash to buy&nbsp;4,710 Bitcoin after GameStop&#8217;s board approved the crypto as a treasury reserve asset last quarter. 
Following the company&#8217;s quarterly results, Wedbush analyst Michael Pachter reiterated GameStop with an <a href="https://www.benzinga.com/analyst-stock-ratings">Underperform rating</a> and price target of&nbsp;$13.50. 
Pachter expects to see continued declines in revenue in the company&#8217;s core business. Although he acknowledged that the <a href="https://www.benzinga.com/news/gaming/25/06/45776150/jensen-huang-says-nintendo-switch-2-has-ai-processors-to-enhance-gameplay-unlike-anything-weve-built-before">Nintendo Switch 2 release</a> could provide a &#8220;transitory bump,&#8221; he expects the trend in overall revenues to be lower. 
&#8220;GME shares trade at a level that overlooks the many challenges ahead,&#8221; the Wedbush analyst said in a note to clients. 
<h3 class="wp-block-heading">How To Buy GME Stock</h3>
Besides going to a brokerage platform to purchase a share &#8211; or fractional share &#8211; of stock, you can also gain access to shares either by buying an exchange traded fund (ETF) that holds the stock itself, or by allocating yourself to a strategy in your 401(k) that would seek to acquire shares in a mutual fund or other instrument. 
For example, in GameStop's case, it is in the Consumer Discretionary sector. An ETF will likely hold shares in many liquid and large companies that help track that sector, allowing an investor to gain exposure to the trends within that segment.
GME Price Action: <a href="http://benzinga.com/quote/GME">GameStop shares</a> traded down to around $28.30 following the print. The stock was bouncing back a bit Wednesday morning, last down 5.31% at $28.55, according to <a href="http://pro.benzinga.com">Benzinga Pro</a>.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/news/gaming/25/06/45850712/microsoft-vs-nintendo-handheld-gaming-console-includes-nvidia-vs-amd-battle-which-one-will-come-out-on-top">Microsoft Vs. Nintendo Handheld Gaming Console Includes Nvidia Vs. AMD Battle: Which One Will Come Out On Top?</a></li>
</ul>
Photo: Shutterstock.

Earnings

Price Target

Movers

What's Going On With GameStop Stock Wednesday?

RBC Capital analyst Mike Dahl maintains Core &amp; Main (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CNM#NYSE">CNM</a>) with a Outperform and raises the price target from $60 to $67.

Analyst Ratings

RBC Capital Maintains Outperform on Core & Main, Raises Price Target to $67

<a href="https://www.nytimes.com/2025/06/11/business/media/disney-universal-midjourney-ai.html" title="https://www.nytimes.com/2025/06/11/business/media/disney-universal-midjourney-ai.html">https://www.nytimes.com/2025/06/11/business/media/disney-universal-midjourney-ai.html</a>
<a href="https://www.nytimes.com/2025/06/11/business/media/disney-universal-midjourney-ai.html" title="https://www.nytimes.com/2025/06/11/business/media/disney-universal-midjourney-ai.html">https://www.nytimes.com/2025/06/11/business/media/disney-universal-midjourney-ai.html</a>

Legal

CMCSA

'Disney and Universal Sue A.I. Firm for Copyright Infringement' -New York Times

RBC Capital analyst Deane Dray maintains Fortive (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FTV#NYSE">FTV</a>) with a Sector Perform and lowers the price target from $79 to $75.

RBC Capital Maintains Sector Perform on Fortive, Lowers Price Target to $75

Stifel analyst Mark Kelley initiates coverage on DoorDash (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DASH#NASDAQ">DASH</a>) with a Hold rating and announces Price Target of $198.

Initiation

DASH

Stifel Initiates Coverage On DoorDash with Hold Rating, Announces Price Target of $198

RBC Capital analyst Matthew Hedberg maintains GitLab (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GTLB#NASDAQ">GTLB</a>) with a Outperform and lowers the price target from $68 to $62.

GTLB

RBC Capital Maintains Outperform on GitLab, Lowers Price Target to $62

During Senate Hearing Reuters Reports Trump FAA Nominee Bryan Bedford Reportedly Says Vows To Hold Boeing "Accountable"

Stifel analyst Mark Kelley initiates coverage on Uber Technologies (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UBER#NYSE">UBER</a>) with a Buy rating and announces Price Target of $110.

Stifel Initiates Coverage On Uber Technologies with Buy Rating, Announces Price Target of $110

RBC Capital analyst Leonid Timashev maintains Insmed (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INSM#NASDAQ">INSM</a>) with a Outperform and raises the price target from $99 to $106.

INSM

RBC Capital Maintains Outperform on Insmed, Raises Price Target to $106

Press Releases

Sportradar Announces Agreement to Acquire IMG ARENA and Its Strategic Portfolio of Global Sports Betting Rights

Sportradar Reports Fourth Quarter and Full Year 2024 Results and Announces Agreement to Acquire IMG Arena and Its Strategic Portfolio of Global Sports Betting Rights

Sportradar Files Its Annual Report on Form 20-F

Sportradar Outlines Growth Strategy and Financial Outlook at Investor Day

Sportradar Announces Launch of Public Offering of Class A Ordinary Shares by Selling Shareholders and Concurrent Share Repurchase

Sportradar Announces Preliminary First Quarter 2025 Financial Results

Sportradar Announces Pricing of Public Offering of Class A Ordinary Shares by Selling Shareholders and Concurrent Share Repurchase

Sportradar Reports First Quarter Results

Gabelli Funds to Host 17th Annual Media & Entertainment Symposium Thursday, June 5, 2025

AMCX

BATRA

CHDN

GENI

LION

MSGS

NXST

RSVR

SBGI

SRAD

TGNA

TSX:RCI

Needham

Morgan Stanley

Benchmark

BTIG

Screenshot 2025-05-29 at 11.55.03 PM

Sports Betting

Emerging Markets

Pushing The Boundaries Of Innovation: How Sportradar Is Setting New Industry Standards

Screenshot 2025-05-20 at 9.13.29 PM

From Concierge Style Sports Betting To AI Suggestions, Sportradar Takes Innovation to The Next Level

Screenshot 2025-03-25 at 5.32.08 PM

Revolutionizing Fan Engagement With Sportradar

Screenshot 2025-02-27 at 7.12.33 PM

The Future Of Sports Betting? Sportradar Technology Fuels Multi-Billion Dollar In-Play Industry

Screenshot 2025-02-20 at 7.39.13 PM

GOOG

Betting On The Future: How Sportradar Merges Sports, AI And Fan Engagement

Untitled design - 2024-12-09T182217.813

Sports

Sportradar Partners With The NBA To Help Bring A New Era Of Sports Viewership To Fans

Comments

Sportradar Gr

Sportradar Gr (SRAD) Opciones

Sportradar Gr (NASDAQ:SRAD) Bolsa, Cadena de Opciones

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL